St. Jude Children's Research Hospital scientists have identified a promising combination approach to treat a rare but catastrophic pediatric brain cancer called atypical teratoid rhabdoid tumor (ATRT).

See how a combo therapy of idasantulin and Selinexor stimulate the p53 pathway through MDM2 and XPO1 to treat atypical teratoid rhabdoid tumors (ATRT)

Selinexor is a covalent inhibitor of the nuclear export receptor exportin 1 (XPO1). Wing, Fung and Kwanten et al. found that selinexor mediates XPO1 degradation through an allosteric molecule glue mec...

Selinexor is a covalent inhibitor of the nuclear export receptor exportin 1 (XPO1). Wing, Fung and Kwanten et al. found that selinexor mediates XPO1 degradation through an allosteric molecule glue mec...

Karyopharm Therapeutics has announced a strategic $100 million financing to expand operations and support growth, notably in myelofibrosis treatments.

Selinexor is a new compound studied for the treatment of liposarcoma, particularly dedifferentiated liposarcoma (DDLPS), where treatment options remain limited. As a first-in-class oral exportin-1 (XPO1) inhibitor, selinexor has shown anti-tumour activity in preclinical models, particularly in MDM2- and CDK4-amplified DDLPS, where it induces apoptosis, inhibits tumour growth and promotes nuclear retention of p53. Preclinical studies have also suggested potential synergy with doxorubicin and eribulin, although these findings have yet to be validated in randomised clinical trials. The phase II/III SEAL trial (NCT02606461) evaluated selinexor versus placebo in patients with advanced, previously treated DDLPS. While the study demonstrated a statistically significant, albeit modest, improvement in median progression-free survival (PFS) from 2.1 to 2.8 months, no overall survival benefit was observed. In addition, selinexor was associated with significant toxicity, including fatigue, nausea and weight loss. Similarly, a phase Ib/II study (NCT03042819) evaluating selinexor in combination with doxorubicin reported a 21% response rate and a median PFS of 5.5 months, although this regimen was also associated with high rates of neutropenia and fatigue. Despite these results, selinexor is not currently approved for the treatment of liposarcoma and its clinical utility remains under investigation. Ongoing studies, such as the SeliSarc trial (NCT04595994) evaluating selinexor in combination with gemcitabine and the NRSTS2021 trial (NCT06239272) evaluating selinexor in paediatric soft tissue sarcoma, aim to further define its role. The results of these studies will be critical in determining whether selinexor can be incorporated into standard sarcoma treatment.

Karyopharm Therapeutics has announced the completion of patient enrollment in the Phase 3 SENTRY trial for myelofibrosis, aiming to redefine treatment options.

Karyopharm Therapeutics has reported its financial results for Q2 2025, highlighting progress in clinical trials and revenue growth. The company anticipates significant developments ahead.

Jalid Sehouli, MD, Charité Universitätsmedizin Berlin, Berlin, Germany, comments on a post-hoc analysis of the ENGOT-EN5/GOG-3055/SIENDO study (NCT03555422), evaluating selinexor...